0000926326-26-000019
SEC filingOmnicell二季度营收利润双增，上调全年non-GAAP EBITDA及EPS指引，业绩超预期。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Total Revenues | $312.2M | $290.6M | +7% |
| Product Revenues | $175.1M | $163.2M | +7.3% |
| Service Revenues | $137.1M | $127.4M | +7.7% |
| Gross Margin (GAAP) | 49.0% | 43.9% | +5.1pp |
| Gross Margin (Non-GAAP) | 50.2% | 44.7% | +5.5pp |
| Income from Operations (GAAP) | $32.4M | $8.1M | — |
| Net Income (GAAP) | $24.3M | $5.6M | — |
| Diluted EPS (GAAP) | $0.52 | $0.12 | — |
| Non-GAAP Net Income | $43.5M | $21.1M | — |
| Non-GAAP Diluted EPS | $0.94 | $0.45 | — |
| Non-GAAP EBITDA | $67.2M | $38.4M | — |
| Non-GAAP EBITDA Margin | 21.5% | 13.2% | +8.3pp |
| Operating Cash Flow | $68.3M | $42.8M | — |
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| Q3 2026 | Total Revenues | $301M - $307M | N/A |
| Q3 2026 | Product Revenues | $169M - $172M | N/A |
| Q3 2026 | Service Revenues | $132M - $135M | N/A |
| Q3 2026 | Non-GAAP EBITDA | $32M - $37M | Non-GAAP |
| Q3 2026 | Non-GAAP EPS | $0.35 - $0.43 | Non-GAAP |
| FY2026 | Total Revenues | $1.225B - $1.245B | N/A |
| FY2026 | Product Revenues | $690M - $700M | N/A |
| FY2026 | Service Revenues | $535M - $545M | N/A |
| FY2026 | Technical Services Revenues | $267M - $272M | N/A |
| FY2026 | SaaS and Expert Service Revenues | $268M - $273M | N/A |
| FY2026 | Product Bookings | $425M - $560M | N/A |
| FY2026 | Annual Recurring Revenue | $660M - $680M | N/A |
| FY2026 | Non-GAAP EBITDA | $175M - $185M | Non-GAAP |
| FY2026 | Non-GAAP EPS | $2.15 - $2.30 | Non-GAAP |
简评
Omnicell 二季度业绩表现强劲，总营收 $312M 同比增长 7%，处于公司预期区间的高端。增长主要由北美及国际市场的 connected devices 组合、SaaS 和 Expert Services 以及 technical services 收入共同驱动。盈利能力大幅改善，GAAP 毛利率从 43.9% 提升至 49.0%，non-GAAP 毛利率从 44.7% 提升至 50.2%，主要得益于产品组合优化、成本管控以及本季度收到的 $15M IEEPA 关税退款（该退款主要降低了产品成本）。GAAP 净利 $24M（EPS $0.52）较去年同期的 $6M（EPS $0.12）大幅增长，non-GAAP 净利 $44M（EPS $0.94）亦显著高于去年同期的 $21M（EPS $0.45）。non-GAAP EBITDA 达 $67M，margin 21.5%，较去年同期的 13.2% 大幅提升 8.3 个百分点。
管理层对业绩表示满意，CEO Randall A. Lipps 强调业绩反映了多元化业务模式的实力、核心药物管理解决方案需求的韧性以及对运营纪律的持续关注。公司基于上半年强劲的盈利表现，上调了 2026 全年 non-GAAP EBITDA 指引至 $175M-$185M、non-GAAP EPS 指引至 $2.15-$2.30，同时收窄了全年营收指引至 $1.225B-$1.245B。不过，公司下调了 Product Bookings 指引至 $425M-$560M，并下调 Annual Recurring Revenue 指引至 $660M-$680M，反映部分增长机会的兑现时间比预期更长。资产负债表保持稳健，现金 $292M，总债务 $168M，循环信贷额度尚有 $350M 可用，经营现金流 $68M 同比显著改善。此外，公司近期宣布 Nnamdi Njoku 升任总裁兼 COO，并新增两个高管职位，显示其对长期增长战略的投入。